Merit Medical Systems
Makes single-use devices for vascular access, intervention, endoscopy, oncology, and cardiac therapies.
Something off on this page? Send us feedback.
Profile
Designs and sells single-use devices for interventional, diagnostic, and therapeutic procedures across cardiovascular and endoscopy markets. Cardiovascular accounts for most sales, spanning vascular access and intervention tools, cardiac and renal therapies, oncology, procedural kits, and OEM supply.
Designs, develops, and manufactures single-use medical devices used in interventional, diagnostic, and therapeutic procedures. Reporting remains split between Cardiovascular and Endoscopy, while the current commercial view groups eight platforms into Foundational and Therapeutic: Access, Cardiac Therapies, Endoscopy, OEM, Oncology, Procedural Solutions, Renal Therapies, and Vascular Intervention.
Builds customer-specific kits, trays, and procedural packs, while the OEM operation supplies components and finished devices to other medical-device manufacturers. Hospitals buy through direct sales teams, distributors, OEM partners, and custom-kit assemblers; clinical education supports adoption.
Sells worldwide and operates manufacturing and packaging sites across North America, Europe, Brazil, and Singapore. Execution depends on product development, regulatory clearance, physician acceptance, reimbursement and pricing pressure, supplier performance, tariffs, and global manufacturing continuity. Each product must be approved under the laws of the country where it is sold.
Company facts
Categories
Key statistics
Year to date +4.6% · Average volume (30d) 984.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Barrington | Target | $106 | $114 | ||
| Jul 31, 2026 | Canaccord Genuity | Target | $99 | $94 | ||
| Jul 31, 2026 | Raymond James | Reiterate | Outperform | $71 | $100 | |
| Jul 31, 2026 | BTIG | Reiterate | Buy | $107 | $105 | |
| Jul 31, 2026 | Needham | Reiterate | Buy | $105 | $101 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.96 | $1.19 | +24.1% | $405.2M | $418.8M | +3.4% | +1.99% |
| Apr 30, 2026Q1 FY26 | $0.84 | $0.94 | +11.9% | $377.6M | $381.9M | +1.1% | −9.05% |
| Feb 24, 2026Q4 FY25 | $0.96 | $1.04 | +8.3% | $389.9M | $393.9M | +1.0% | −3.88% |
| Oct 30, 2025Q3 FY25 | $0.82 | $0.92 | +12.2% | $388.3M | $384.2M | −1.1% | +5.42% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $354.3M | $382.0M | $384.3M | $394.2M | $381.9M | $418.8M | |
| Gross profit | $171.5M | $184.2M | $186.5M | $195.4M | $184.8M | $215.2M | |
| Operating income | $50.8M | $46.8M | $42.8M | $54.1M | $44.0M | $60.5M | |
| Net income | $30.1M | $32.6M | $27.8M | $38.0M | $41.0M | $38.8M | |
| Diluted EPS | $0.49 | $0.54 | $0.46 | $0.63 | $0.68 | $0.65 | |
| Gross margin | 48.4% | 48.2% | 48.5% | 49.6% | 48.4% | 51.4% | |
| Operating margin | 14.3% | 12.2% | 11.1% | 13.7% | 11.5% | 14.5% |
Fiscal years (4-quarter sums)FY21 $1.07B · FY22 $1.15B · FY23 $1.26B · FY24 $1.36B · FY25 $1.51B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $448.7M · Total debt $820.1M · Total assets $2.86B · Shareholders' equity $1.68B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 59.71M · Float 58.27M · 97.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.46M | 15.85% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 3.47M | 5.82% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.59M | 4.34% | 13F | Aug 13, 2026 |
| State Street Corp | 2.47M | 4.14% | 13F | Aug 7, 2026 |
| Conestoga Capital Advisors, LLC | 1.98M | 3.32% | 13F | Jul 24, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Neil W. Peterson | officer: CHIEF OPERATING OFFICER | −7,500 | $90.45 |
| Aug 4, 2026 | Neil W. Peterson | officer: CHIEF OPERATING OFFICER | −21,449 | $85.00 |
| May 11, 2026 | Christian Adam Smith | officer: Chief Commercial Officer | +1,626 | $61.00 |
| May 7, 2026 | Brian G. Lloyd | officer: CHIEF LEGAL OFFICER, SECRETARY | +2,000 | $62.63 |
| May 7, 2026 | Lynne N. Ward | director | −5,000 | $62.61 |
Peers
- Boston Scientific
Broad overlap in cardiovascular, peripheral, and endoscopy devices
- Teleflex
Direct vascular access and interventional-device overlap
- BD
Peripheral intervention, biopsy, drainage, and access overlap
- Medtronic
Large-scale overlap in cardiac, vascular, spine, and endoscopy
- Abbott
Cardiac intervention overlap in EP, rhythm, and vascular devices
- Edwards Lifesciences
Named cardiac-intervention peer in structural heart procedures
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Merit Medical Systems | $90.49 | +0.10% | $5.40B | 37.4 | 20.7 | 3.4 | +9.5% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Teleflex | $139.67 | −0.01% | $6.18B | — | 15.2 | 2.4 | −27.0% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Edwards Lifesciences | $91.14 | +1.04% | $51.94B | 51.8 | 28.7 | 8.0 | +13.6% |
| Median | 36.2 | 15.2 | 3.3 | +8.7% |